The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death.
抗 FRα 抗体药物偶联物 Luveltamab Tazevibulin 在非小细胞肺癌临床前模型中显示出疗效，并诱导免疫原性细胞死亡
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-24-0649
Yuan Robert, McGeehan Andrew, Zhou Sihong, Cheng Christine, Armanini Mark, Smith Jennifer, Embry Millicent, Pena Rhoneil, Lewis Danielle K, Hernandez Genevive, Bajjuri Krishna, Tran Cuong, Yin Gang, Abrahams Cristina, Li Xiaofan, Gerber Hans-Peter, Yam Alice, Kiefel Helena
